Actively Recruiting
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
Led by Tongji Hospital · Updated on 2022-09-15
80
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs ， to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.
CONDITIONS
Official Title
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- More than 18 years old
- Patients with pathologically confirmed breast cancer
- Sign the informed consent form
You will not qualify if you...
- Pregnant women
- Severe underlying diseases that cannot cooperate with PET examination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
TongjiHospital
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
Z
ZHU XIAOHUA, DR
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here